Literature DB >> 17423803

Myelofibrosis: Review of clinical and pathological features in fourteen dogs.

B Hoff, J H Lumsden, V E Valli, S A Kruth.   

Abstract

A clinicopathological study was performed on 14 dogs with myelofibrosis (MF), in order to correlate clinical, laboratory, and histomorphological parameters and investigate factors of prognostic significance. The clinical signs included fatigue, weight loss, anorexia, and diarrhea. Physical findings included pale mucous membranes and wasting/emaciation. The major laboratory observations were moderate to severe, poorly-responsive anemia with various degrees of marrow cellularity and fibrosis. All dogs with severe, non-responsive anemia should have a bone marrow core biopsy, stained for connective tissue, in order to detect myelofibrosis. Myelofibrosis regressed in six dogs.

Entities:  

Year:  1991        PMID: 17423803      PMCID: PMC1481457     

Source DB:  PubMed          Journal:  Can Vet J        ISSN: 0008-5286            Impact factor:   1.008


  32 in total

1.  A clinical and pathological study of seventy cases of myelofibrosis.

Authors:  J A PITCOCK; E H REINHARD; B W JUSTUS; R S MENDELSOHN
Journal:  Ann Intern Med       Date:  1962-07       Impact factor: 25.391

2.  Lupus anticoagulant in myelofibrosis.

Authors:  B Bernhardt; M Valletta
Journal:  Am J Med Sci       Date:  1976 Sep-Oct       Impact factor: 2.378

3.  Bone marrow fibre production in myelofibrosis: a quantitative study.

Authors:  S A Bentley; C J Herman
Journal:  Br J Haematol       Date:  1979-05       Impact factor: 6.998

4.  Myelofibrosis and prostaglandins: effect of prostaglandin E1 on colony-forming cells (CFU-GM).

Authors:  M Aglietta; W Piacibello; F Gavosto
Journal:  Br J Haematol       Date:  1981-05       Impact factor: 6.998

5.  The pathogenesis of myelofibrosis in myeloproliferative disorders.

Authors:  J E Groopman
Journal:  Ann Intern Med       Date:  1980-06       Impact factor: 25.391

6.  Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis.

Authors:  E Rondeau; P Solal-Celigny; D Dhermy; M Vroclans; N Brousse; J F Bernard; P Boivin
Journal:  Br J Haematol       Date:  1983-03       Impact factor: 6.998

7.  Idiopathic myelofibrosis: a possible role for immune-complexes in the pathogenesis of bone marrow fibrosis.

Authors:  F C Cappio; R Vigliani; A Novarino; G Camussi; D Campana; F Gavosto
Journal:  Br J Haematol       Date:  1981-09       Impact factor: 6.998

8.  Platelet factor-4 excretion in myeloproliferative disease: implications for the aetiology of myelofibrosis.

Authors:  S A Burstein; T W Malpass; E Yee; M Kadin; M Brigden; J W Adamson; L A Harker
Journal:  Br J Haematol       Date:  1984-07       Impact factor: 6.998

9.  Origin of human bone marrow fibroblasts.

Authors:  D W Golde; W G Hocking; S G Quan; R S Sparkes; R P Gale
Journal:  Br J Haematol       Date:  1980-02       Impact factor: 6.998

10.  Acute myelofibrosis: a report of three cases.

Authors:  D R Fabich; P C Raich
Journal:  Am J Clin Pathol       Date:  1977-04       Impact factor: 2.493

View more
  2 in total

1.  Familial cutaneous vasculopathy of German shepherds: clinical, genetic and preliminary pathological and immunological studies.

Authors:  J A Weir; J A Yager; J L Caswell; W M Parker; I B Johnstone; P K Basrur; C Emms
Journal:  Can Vet J       Date:  1994-12       Impact factor: 1.008

2.  Targeted sequencing of candidate gene regions for myelofibrosis in dogs.

Authors:  Amelia G Campbell; Davis M Seelig; Joan D Beckman; Katie M Minor; Daniel A Heinrich; Steven G Friedenberg; Jaime F Modiano; Eva Furrow
Journal:  J Vet Intern Med       Date:  2022-07-11       Impact factor: 3.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.